Collegium Pharmaceutical, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-12-31 was 149.13K shares.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 25.27K shares, a 85.56% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 8.22K shares, a 94.02% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 18.69K shares, a 89.84% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 637.92K shares, a 216.89% increase from fiscal 2019.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 201.31K shares.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 349.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2020-12-31 | 637.92K shares 10-K · filed 2021-02-25 | |
| 2019-12-31 | 149.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 201.31K shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 25.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | |
| 2019-06-30 | 8.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | |
| 2019-03-31 | 18.69K shares 10-Q · filed 2019-05-08 | |
| 2018-09-30 | 13.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 553.05K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2018-06-30 | 137.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | 543.68K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2018-03-31 | 183.99K shares 10-Q · filed 2018-05-09 | 513.11K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-12-31 | 218.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 349.78K shares 10-K · filed 2019-02-27 |
| 2017-09-30 | 4.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | |
| 2017-06-30 | 106.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | |
| 2017-03-31 | 20.65K shares 10-Q · filed 2017-05-10 | |
| 2016-09-30 | 17.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2016-06-30 | 15.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | |
| 2016-03-31 | 23.75K shares 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |